Merck Gets China OK for Keytruda as Monotherapy for First-Line NSCLC Treatment
02 Oktober 2019 - 2:39PM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said China's National Medical
Products Administration approved the company's cancer drug Keytruda
as monotherapy for the first-line treatment in certain patients
with non-small cell lung cancer.
The Kenilworth, N.J., drug maker said the approval covers
patients with locally advanced or metastatic non-small cell lung
cancer whose tumors express PD-L1 as determined by a NMPA-approved
test, with no EGFR or ALK genomic tumor aberrations.
Merck said Keytruda is the first anti-PD-1 therapy approved in
China as both monotherapy and in combination with chemotherapy for
the first-line treatment of appropriate patients with non-small
cell lung cancer, the most common type of lung cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 02, 2019 08:24 ET (12:24 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
